NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Ozempic isn’t just for weight loss—studies show it could help prevent strokes. Discover what this means for you, and what ...

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...

As the list of health benefits of semaglutide drugs grows, perhaps it is time to think about assessing their impact on people ...

If you’re one of the many people using Ozempic (semaglutide) to manage type 2 diabetes or for weight loss under medical ...

Clifford Segil, DO, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA, agrees. “Lowering a person’s ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

CINCINNATI (WKRC) - Customs and Border Protection officers seized nearly 55,000 counterfeit and unapproved medications ...

Lizzo opened up about her dramatic weight loss in a recent interview, and the singer says that even though she’s dropped down ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...